Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles

Toxicology in Vitro

Volumn 19, Issue 5, 2005, Pages 621-629

  Bogni, Alessia ^a,b   Monshouwer, Mario ^c   Moscone, Anna ^c   Hidestrand, Mats ^d   Ingelman Sundberg, Magnus ^d   Hartung, Thomas ^a,b   Coecke, Sandra ^a  

^a JOINT RESEARCH CENTRE   (Italy)

^b UNIVERSITY OF KONSTANZ   (Germany)

^c NERVIANO MEDICAL SCIENCES   (Italy)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cytochrome P450 2D6; Haloperidol; In vitro; Polymorphism; V79 Chinese hamster cells

Indexed keywords

8 [3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]PROPYLCARBAMOYL] 3 METHYLFLAVONE; BUFURALOL; CYTOCHROME P450 2D; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DRUG; HALOPERIDOL; IMIPRAMINE; MIANSERIN; REC 27 0110; SPARTEINE; TAMOXIFEN; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ARTICLE; CELL STRAIN V 79; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG METABOLISM; GENETIC ENGINEERING; GENETIC POLYMORPHISM; METABOLISM; MICROSOME; NONHUMAN; PROTEIN EXPRESSION; YEAST CELL;

ALLELES; ANIMALS; CELLS, CULTURED; CRICETINAE; CYTOCHROME P-450 CYP2D6; ETHANOLAMINES; HUMANS; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY;

CRICETINAE; CRICETULUS GRISEUS;

EID: 19344367709     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2005.04.001     Document Type: Article

References (26)

1. T.E. Bapiro, J.A. Hasler, M. Ridderstrom, and C.M. Masimirembwa The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6*17 (CYP2D6*17) variant. Potential implication for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African population Biochem. Pharmacol. 64 2002 1387 1398
2. J. Brockmoller, J. Kirchheiner, J. Schmider, S. Walter, C. Sachse, B. Muller-Oerlinghausen, and I. Roots The impact of the hCYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment Clin. Pharmacol. Ther. 72 2002 438 452
3. J. Bylund, M. Hidestrand, M. Ingelman-Sundberg, and E.H. Oliw Identification of hCYP4F8 in human seminal vesicles as a prominent 19-hydroxylase of prostaglandin endoperoxides J. Biol. Chem. 275 2000 21844 21849
4. S.E. Clarke, and P. Jeffrey Utility of metabolic stability screening:Comparison of in vitro and in vivo clearance Xenobiotica 31 2001 591 598
5. A.K. Daly, J. Brockmoller, F. Broly, M. Eichelbaum, W.E. Evans, and F.J. Gonzalez Nomenclature for human hCYP2D6 alleles Pharmacogenetics 6 1996 193 201
6. TM: An analytical tool for predicting drug metabolism and metabolism dependent toxicity for humans Nova. Acta. Leopoldina 329 2003 125 132
7. M.G. Eichelbaum, and A.S. Gross The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspect Pharmacol. Ther. 46 1990 377 394
8. M. Eichelbaum, N. Spannbrucker, and H.J. Dengler Influence of the defective metabolism of sparteine on its pharmacokinetics Eur. J. Clin. Pharmacol. 16 1979 189 194
9. F.J. Gonzalez, R.C. Skoda, S. Kimura, M. Umeno, U.M. Zanger, D.W. Nebert, H.V. Gelboin, J.P. Hardwick, and U.A. Meyer Characterization of the common genetic defect in humans deficient in debrisoquine metabolism Nature 331 1988 442 446
10. T. Hartung, G. Gstraunthaler, S. Coecke, D. Lewis, O. Blanck, and M. Balls Good cell culture practice (GCCP)-eine Initiative zur Standardisierung und QualitaTssicherung von in vitro Arbeiten Die Etablierung einer ECVAM Task Force on GCCP Altex 18 2001 75 78
11. J.B. Houston Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance Biochem. Pharmacol. 47 1994 1469 1479
12. M. Ingelman-Sundberg Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity Pharmacogenom. J. 5 2005 6 13
13. M. Ingelman-Sundberg, and I. Johansson The molecular genetic of the human drug metabolising cytochrome P450 Advances in drug metabolism in man EUR 15439 (Pacifici GM and Fracchia GN) 1995 Office for Official Publications of the European Communities Luxembourg 545 585
14. N. Krebsfaenger, T.E. Mürdter, U. Zanger, M.F. Eichelbaum, and J. Doehmer V79 Chinese hamster cells genetically engineered for polymorphic cytochromes P450 2D6 and their predictive value for humans Altex 20 2003 141 154
15. T. Kronbach Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450 II D6 Methods Enzymol. 206 1991 509 517
16. A. Mahgoub, J.R. Idle, L.G. Dring, R. Lancaster, and R.L. Smith Polymorphic hydroxylation of debrisoquine in man Lancet 2 1977 584 586
17. Y. Naritomi, S. Terashita, S. Kimura, A. Suzuki, A. Kagayama, and Y. Sugiyama Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans Drug Metab. Dispos. 29 2001 1316 1324
18. R.S. Obach Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes Drug Metab. Dispos. 27 1999 1350 1359
19. R.S. Obach, and A. Reed-Hagen Measurements of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach Drug Metab. Dispos. 30 2002 831 837
20. R.S. Obach, J.G. Baxter, T.E. Liston, B.M. Silber, B.C. Jones, and F. MacIntyre The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data J. Pharmacol. Exp. Ther. 283 1997 46 58
21. M. Oscarson, M. Hidestrand, I. Johannsson, and M. Ingelman-Sundberg A combination of mutations in the CYP2D6*17 (CAP2D6Z) allele causes alterations in enzyme function Mol. Pharmacol. 52 1997 1034 1040
22. L. Pan, and F.M. Belpaire In vitro study on the involvement of hCYP1A2, hCYP2D6 and hCYP3A4 in the metabolism of haloperidol and reduced haloperidol Eur. J. Clin. Pharmacol. 55 1999 599 604
23. S. Panserat, L. Sica, N. Gerard, H. Mathieu, E. Jacqz-Aigrain, and R. Krishnamoorthy hCYP2D6 polymorphism in a Gabonese population: contribution of the hCYP2D6*2 and hCYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype Br. J. Clin. Pharmacol. 47 1999 121 124
24. Y. Ramamoorthy, R.F. Tyndale, and E.M. Sellers Cytochrome P450 2D6*1 and cytochrome P450 2D6*10 differ in catalytic activity for multiple substrates Pharmacogenetics 11 2001 477 487
25. Y. Shibata, H. Takahashi, and Y. Ishii A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum Drug Metab. Dispos. 28 2000 1518 1523
26. A. Wennerholm, C. Dandara, J. Sayi, J.O. Svensson, Y.A. Abdi, and M. Ingelman-Sundberg The African-specific hCYP2D6*17 allele encodes an enzyme with changed substrate specificity Clin. Pharmacol. Ther. 71 2002 77 88